Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

Description

This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq \[18F\]florbetaben and PET scanning of patients with suspected cardiac amyloidosis.

Conditions

Cardiac Amyloidosis, AL Amyloidosis, ATTR Amyloidosis

Talk to us

Study Overview

On this page

Study Details

Study overview

This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq \[18F\]florbetaben and PET scanning of patients with suspected cardiac amyloidosis.

An Open-label, Multi-center, Non-randomized Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of [18F]Florbetaben Positron Emission Tomography (PET) Imaging to Diagnose Cardiac AL Amyloidosis

Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

Condition
Cardiac Amyloidosis
Intervention / Treatment

-

Contacts and Locations

Kansas City

St Luke's Hospital, Kansas City, Kansas, United States, 64111

Philadelphia

University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104

Pittsburgh

University of Pittsburgh, Pittsburgh, Pennsylvania, United States, 15213

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Males and females age ≥18 years
  • * Able to understand, sign and date written informed consent
  • * Written informed consent must be obtained before any assessment is performed
  • * Subjects being considered for a possible diagnosis of cardiac amyloidosis by
  • * 1. One of the following conditions:
  • * Established systemic amyloidosis without proven cardiac involvement,
  • * Known plasma cell dyscrasia (MGUS, multiple myeloma),
  • * Pathological free light chain levels in urine or serum,
  • * Presence of heart failure with preserved ejection fraction
  • * 2. AND one of the following parameters, indicative of cardiac manifestation:
  • * Mean (left ventricular (LV) wall + septum) thickness \>12mm as measured by echocardiography in absence of other known cause of left ventricular hypertrophy (LVH),
  • * NT-proBNP \>335 ng/L
  • * Planned diagnostic procedure to establish diagnosis and cardiac involvement (e.g., endomyocardial biopsy or extracardiac biopsy in conjunction with cardiac magnetic resonance imaging/echocardiography or bone scintigraphy)
  • * Female subjects must be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or post-menopausal for at least 1 year (no menses for 12 months without an alternative medical cause). If they are of child-bearing potential, they must commit to use of a highly effective contraceptive measure for at least one week following the PET scan
  • * Male subjects and their partners of childbearing potential must commit to the use of a highly effective method of contraception for a minimum of 90 days following the PET scan
  • * Male subjects must commit to not donate sperm for a minimum of 90 days after the PET scan
  • * Any known allergic reactions or hypersensitivity towards any compound of the study drug
  • * Severe hepatic impairment (AST/ALT \>5 x ULN; bilirubin \>3 x ULN)
  • * Inability to lay flat for up to 60 min
  • * Pregnant, lactating or breastfeeding
  • * Unwilling and/or unable to cooperate with study procedures
  • * Having been administered a radiopharmaceutical within 10 radioactive half-lives prior to study drug administration in this study

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Life Molecular Imaging GmbH,

Andrew Stephens, MD, PhD, STUDY_DIRECTOR, Life Molecular Imaging

Study Record Dates

2025-06